Analyst Charles Brennan of Jefferies maintained a Buy rating on Sage Group plc (SGE – Research Report), retaining the price target of ...

Sage Therapeutics, Inc. SAGE reported a loss of $1.53 per share for the third quarter of 2024, wider than the Zacks Consensus ...

Shares of Sage Therapeutics (NASDAQ:SAGE) fell 18% post-market after the company released its Q3 earnings report and said ...

The Cambridge, Mass.-based company SAGE said it would give priority to the launch of zurzuvae, a treatment for postpartum depression, and focus on a study readout from its dalzanemdor as a ...

SAGE Therapeutics (SAGE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Sage 50 Accounting now works with Sage HR, the company's multi-module human resources application. It starts at $6 per user ...

Sage Therapeutics Inc. is laying off more than 165 employees as the biotech company tries to conserve cash after multiple setbacks to its pipeline. The job cuts will affect about one-third of its ...

Ofer’s Quantum Pacific acquired 767 Third Avenue in Midtown East for $88 million, the Commercial Observer reported. The ...

Sage operates a patient support center on Brier Creek Parkway in Raleigh. According to its latest quarterly earnings report, the company has an operating lease for 15,525 square feet of space in ...

The Sage Group Plc engages in the provision of ... and North America. The company was founded by David Goldman, Paul Muller, and Graham Wylie in 1981 and is headquartered in Newcastle-upon-Tyne ...

专注于脑健康疾病的生物制药公司Sage Therapeutics股价触及52周新低，跌至5.63美元。这一价格点反映了该公司的显著下滑，过去一年股价变动幅度达-70.71%。由于公司正经历临床试验挫折和生物科技股整体市场下滑的艰难时期，投资者保持谨慎态度。跌至今年最低点凸显了该板块的波动性以及市场对Sage业绩和前景的反应。 在其他近期新闻中，Sage Therapeutics报告其产后抑郁症(P ...